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A successful cellular response to virus infection is
essential for evolutionary survival. In plants, arthro-
pods, and nematodes, cellular antiviral defenses
rely on RNAi. Interestingly, the mammalian response
to virus is predominantly orchestrated through inter-
feron (IFN)-mediated induction of antiviral proteins.
Despite the potency of the IFN system, it remains un-
clear whether mammals also have the capacity to
employ antiviral RNAi. Here, we investigated this by
disabling IFN function, small RNA function, or both
activities in the context of virus infection. We find
that loss of small RNAs in the context of an in vivo
RNA virus infection lowers titers due to reduced tran-
scriptional repression of the host antiviral response.
In contrast, enabling a virus with the capacity to
inhibit the IFN system results in increased titers.
Taken together, these results indicate that small
RNA silencing is not a physiological contributor to
the IFN-mediated cellular response to virus infection.INTRODUCTION
To successfully generate progeny virions and ensure productive
replication, a virus must have access to the raw materials of its
host cell. In response, the host cell must rapidly recognize the
presence of the virus and employ a defense aimed at halting
the infection. This arms race has resulted in an evolutionary track
record of countless measures and countermeasures employed
by both entities. In plants, arthropods, and nematodes, cells
recognize the formation of double-stranded RNA (dsRNA) as a
foreign structure indicative of virus infection (Kemp and Imler,
2009). This pathogen-associated molecular pattern (PAMP) is
then processed in a variety of means to generate virus-specific
small interfering RNAs (vsiRNAs) through an RNase III family of
nucleases such as Dicer (Ding and Voinnet, 2007; Hutva´gner
and Zamore, 2002; Sabin et al., 2013). vsiRNAs are then loaded
into an RNA-induced silencing complex (RISC) and subse-
quently used to guide it to complementary RNA (Ding and Voin-
net, 2007). This system, generally referred to as RNAi, is capable114 Cell Reports 8, 114–125, July 10, 2014 ª2014 The Authorsof cleaving viral mRNA in an enzymatic fashion and successfully
inhibiting replication (Ratcliff et al., 1999; Zamore et al., 2000). In
response to this effective defense, plant and arthropod viruses
have evolved antagonists to many aspects of the vsiRNA
biogenesis pathway (Chao et al., 2005; Li et al., 2002; Nayak
et al., 2010; Qi et al., 2012; van Rij et al., 2006).
Interestingly, the cellular response to virus in mammals is also
initiated by the detection of dsRNA or other foreign nucleic-acid-
based structures (Bowie and Unterholzner, 2008). However, un-
like the situation with plants and arthropods, detection of dsRNA
results in the culmination of a cytokine-mediated response. That
is, PAMP detection in mammalian cells results in the activation of
host kinases and transcription factors that result in the induction
of type I and III interferons (IFN-I and IFN-III; Rauch et al., 2013).
IFN induction can act in both an autocrine and paracrine manner
to promote the upregulation of hundreds of IFN-stimulated
genes (ISGs) (Schoggins and Rice, 2011). These genes work in
concert to slow virus replication and provide the necessary
time for the adaptive response to clear the infection. Included
in the list of ISGs are host products that inhibit transcription,
translation, and cellular transport, as well as genes involved in
cell death and the release of chemokines to recruit immune cells
to the site of infection (Schoggins and Rice, 2011). As is the case
for arthropod and plant pathogens that inhibit RNAi, viruses that
infect mammals also have evolved proteins to antagonize many
aspects of the IFN-I and IFN-III responses (Weber et al., 2003).
Despite extensive research aimed at defining the mammalian
response to virus infection, it still remains controversial whether
RNAi is also a component of mammalian cells (Umbach and
Cullen, 2009). Evidence for RNAi in mammals includes the evolu-
tionary conservation and utilization of small RNAs in the form of
miRNAS (Bartel, 2004). Like vsiRNAs, these 19–21 nt duplex
RNAs are generated by RNase III nucleases, load into a RISC,
and mediate posttranscriptional silencing (Bartel, 2004). Given
the conservation of this pathway and the required nucleases, it
remains tempting to speculate that small RNAs, or themachinery
itself, could function in an antiviral fashion. This concept is further
supported by the fact that many dsRNA-binding proteins that
antagonize virus detection in mammals also disrupt RNAi (Cullen
et al., 2013; Fabozzi et al., 2011; Garcı´a-Sastre et al., 1998;
Haasnoot et al., 2007; Li et al., 2004; Prins et al., 2010). Although
this may reflect the fact that both systems are dependent on
dsRNA detection and processing, a recent paper from our own
group identified a bona fide inhibitor of small RNAs from poxvi-
ruses (Backes et al., 2012), leading many to speculate that as-
pects of RNAi are indeed conserved in mammals.
Although limited evidence has supported a claim for RNAi in
mammals, other experiments have strongly suggested that small
RNAs are not a component of the vertebrate response to infec-
tion. For example, an engineered influenza A virus (IAV) lacking
a dsRNA antagonist was shown to regain full virulence when
administered to mice lacking IFN signaling capacity (Garcı´a-
Sastre et al., 1998). If RNAi contributes to the mammalian
response to virus infection, one would suppose that in an IFN-
independent model system, lack of a dsRNA antagonist would
still demonstrate some level of attenuation. Furthermore, incor-
poration of miRNA target sites into the genomes of countless vi-
ruses can induce attenuation, suggesting that these viruses have
not needed to evolve countermeasures for small RNA silencing
(tenOever, 2013). The debate about RNAi in mammals, however,
has further intensified with the advent of deep sequencing.
Profiling of small RNAs from virus infection has demonstrated
detectable pools of virus-derived small RNAs that could theoret-
ically serve a role in RNAi, although these small RNA pools
remain unchanged in the absence of Dicer and may actually be
the by-product of ISGs such as RNaseL (Girardi et al., 2013; Par-
ameswaran et al., 2010). Although there is no clear consensus
about how these small RNAs are generated and how they might
function, the idea of mammalian RNAi recently gained significant
traction in the scientific community following the characteriza-
tion of a mutant nodavirus in both stem cells and immortalized
fibroblasts (Li et al., 2013; Maillard et al., 2013).
In an effort to formally address whether small RNAs signifi-
cantly contribute to the mammalian response to virus infection,
we generated a recombinant RNA virus with the capacity to
disrupt either RISC-associated silencing or the IFN-mediated
response. We demonstrate that we can give vesicular stomatitis
virus (VSV) the capacity to eliminate RISC-associated small
RNAs through the expression of vaccinia virus (VACV) VP55
(VSV-VP55) or block detection and subsequent IFN induction
with the addition of IAV NS1 (VSV-NS1). Interestingly, we find
that whereas VSV-NS1 replicates to higher titers in vivo, VSV-
VP55 is attenuated. Furthermore, we find that attenuation is
the result of an enhancement of the IFN response, in agreement
with a recent report that miRNAs suppress the basal levels of
antiviral transcripts (Seo et al., 2013). Profiling the transcriptome
of these infections also provided us with a comprehensive list of
endogenous miRNA targets in the context of infection. To deter-
mine whether small RNAs contributed in the absence of the IFN
response, we also administered VSV-VP55 to IFN-I and IFN-III
receptor knockout mice. In this model system, virus attenuation
of VP55 was lost, but the degradation of small RNAs still failed to
increase overall virus titers. Taken together, these results indi-
cate that the cellular response to virus infection is independent
of small RNA silencing and is mediated exclusively by IFNs.
RESULTS
Small RNA Profiling of Virus-Infected Cells
Given the recent claims of RNAi inmammals, we sought to define
the profile of small RNAs in the context of a spectrum of RNAvirus infections. To this end, we cloned and deep sequenced to-
tal nucleotide pools in the range of 18–25 nt from cells infected
with viruses from diverse families, including Orthomyxoviridae
(IAV), Togaviridae (Sindbis virus [SV]), Bornaviridae (Borna dis-
ease virus [BDV]), and Rhabdoviridae (VSV; Table S1). Small
RNA sequencing reads were then consolidated and mapped to
the respective virus genomes. For each virus infection, small
RNA reads could be assembled into contigs with complete
genomic coverage. In agreement with published literature,
captured small RNA reads were readily detectable in all infec-
tions: 0.04%, 18.4%, 24.1%, and 0.05% of total small RNA
reads mapped to the BDV, IAV, SV, and VSV genomes, respec-
tively (Figure 1A; Donaszi-Ivanov et al., 2013; Girardi et al., 2013;
Parameswaran et al., 2010; Sabin et al., 2013). With the excep-
tion of VSV, virus-derived small RNAs failed to show a size pref-
erence indicative of RNAi activity (Figure 1A). Interestingly, when
the size distribution of the VSV reads were plotted, the dominant
size was 22 nt and there was an enrichment for sequence reads
thatmapped to the ends of the genome, reminiscent of the RNAi-
like activity recently described in mammalian cells (Figures 1A
and 1B; Li et al., 2013). However, it should be noted that these
two most abundant VSV-derived small RNAs, which could be
detected by small RNA northern blot, were Dicer independent
(Figures 1C and 1D). Taken together, these data suggest that
VSV may be a good model for obtaining additional evidence
for or against a small RNA-mediated antiviral defense in
mammals.
VSV Does Not Encode an Inhibitor of Small RNA
Silencing
To probe whether RNAi activity contributed to the cellular
response to VSV infection, we next determined whether VSV en-
coded a suppressor of RNAi. Although VSV has been found to be
sensitive to the RNAi system of arthropods and nematodes, we
wanted to ensure that small RNAs could additionally target
VSV in the context of our mammalian systems (Mueller et al.,
2010; Wilkins et al., 2005). To this end, we cloned four perfect
target sites for the host hematopoietic cell-specific miR-142 as
a 30 UTR of the Large (L) polymerase mRNA as previously
described (Figure 2A; Kelly et al., 2010). In agreement with pub-
lished literature, we found that endogenous miR-142 processing
and silencing potential were unperturbed in miR-142-express-
ing, macrophage-derived RAW cells in response to VSV infec-
tion, as titers were reduced by 2 logs when the miR-142 target
sites were present (Figure 2B; Kelly et al., 2008, 2010). In
contrast, in the absence of miR-142, all viruses replicated to
comparable levels (Figures 2C and S1). Furthermore, insertion
of a primary miRNA (miR-124) into VSV demonstrated that in
the context of infection, the capacity to process hairpins was
not compromised (Figure 2D). These results are in agreement
with numerous published studies demonstrating the successful
engineering of mammalian viruses to be silenced by or produce
small RNAs in the mammalian host (Barnes et al., 2008; Cawood
et al., 2009; Chua et al., 2013; Edge et al., 2008; Kelly et al., 2008;
Langlois et al., 2012a, 2012b, 2013; Perez et al., 2009; Pham
et al., 2012; Shapiro et al., 2010, 2012; Varble et al., 2010,
2013). Taken together, these data suggest that RNA virus infec-
tion in mammalian cells results in large pools of small RNAs andCell Reports 8, 114–125, July 10, 2014 ª2014 The Authors 115
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Figure 1. Small RNA Profiling of Virus-Infected Cells
(A) RNA-seq reads (18–25 nt) obtained from glial cells persistently infected with BDV or from fibroblasts infected with IAV, SV, and VSV (moi of 1 for 12 hr) were
analyzed for size distribution.
(B) VSV-derived reads from (A) were aligned for their distribution across the genome.
(C) Northern blot analysis of wild-type (MEF) and dicer-deficient (Dcr/) cells infected with VSV (moi of 1 for 9 hr) for VSV-derived small RNA VSV318, miR-93,
and U6.
(D) Northern blot analysis of MEF and Dcr/ cells infected with VSV (moi of 1 for 9 hr) for VSV-derived small RNA VSV11161, miR-93, and U6.
See also Table S1.that RISC function is not impaired during the early stages of
infection.
Engineering an RNA Virus with the Capacity to Disrupt
Small RNA Function
We recently characterized a single VACV protein, termed VP55,
that was both necessary and sufficient for the tailing of RISC-
associated host miRNAs (Backes et al., 2012). We found that
VP55 indiscriminately added nontemplated adenosines specif-
ically to RNAs that are associated with RISC, resulting in their
rapid degradation (Backes et al., 2012). Although we postulated
that this activity stemmed from the evolutionary ancestry of en-
tomopox viruses, which needed to block vsiRNAs, it remained
possible that the virus-derived small RNAs themselves provided
an inherent protection to virus in mammals, given the recent re-
ports on such activity (Li et al., 2013; Maillard et al., 2013).
To assess the contribution of small RNAs to the mammalian
response to virus, we sought to insert VP55 into VSV to enable
the virus to block small RNA-mediated silencing. To this end,116 Cell Reports 8, 114–125, July 10, 2014 ª2014 The Authorswe utilized a VP55 variant that was identified following mutagen-
esis studies and was found to have increased protein stability
and activity (Figure S2). VP55 T109A (herein referred to simply
as VP55) was introduced between the Glycoprotein (G) and L
RNA-dependent RNA polymerase (RdRp) genes using the ca-
nonical initiation and termination sequence of the Nucleoprotein
(NP) gene (Figure 3A). Incorporation of VP55 into VSV (VSV-
VP55), as well as a matched control virus with a comparable
RNA insert but lacking an open reading frame (VSVctrl), was
used to infect fibroblasts (Figure 3B). At 12 hr postinfection,
VSV-VP55 demonstrated robust expression of the VACV protein.
Furthermore, this expression correlated with the capacity to
tail and degrade exogenously expressed miR-124 while not im-
pacting VSV leader RNA or the splicing RNA component U6
(Figure 3C).
To determine whether VSV-based expression of VP55 was
sufficient to give the virus the capacity to block RNAi, we next
transfected exogenous vsiRNAs directed against NP. To permit
VP55-mediated tailing of the vsiRNA, we synthesized duplex
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Figure 2. VSV Does Not Encode an Inhibitor
of RNAi
(A) Schematic of the VSV genome engineered to
encode four perfectly complementary miR-142
target (VSV142T) or four scrambled sites (VSVscbl)
in the 30 UTR of the mRNA encoding for the L
protein.
(B and C) Multicycle growth curve of VSVctrl,
VSV142T, and VSVscbl on (B) RAW cells or (C)
dicer-deficient cells (Dcr/). Supernatants were
analyzed at the indicated time points by plaque
assay.
(D) Northern blot analysis of BHK transfected with
miR-124 expressing plasmid (p124) or infectedwith
VSV expressing miR-124 (VSV-124, moi of 1 for
16 hr) for miR-124 and U6.
See also Figure S1.RNA lacking 20-O-methylation, as this chemistry renders small
RNAs resistant to VP55 tailing (Backes et al., 2012). Transfection
of unmodified 21 nt RNA duplexes composed of a scrambled
sequence (scbl) or a complement of NP was followed by virus
infection at a high multiplicity of infection (moi). At 10 hr postin-
fection, we analyzed whole-cell lysates by western blot using a
polyclonal antibody that recognizes the viral glycoprotein (G),
the viral matrix protein (M), and NP (Figure 3D). These analyses
demonstrated that VSVctrl was highly susceptible to NP vsiRNA
silencing, in contrast to VSV-VP55, which showed no evidence of
NP targeting. Furthermore, sequencing of miR-146b, a miRNA
that has been shown to be induced in response to virus infection
(Taganov et al., 2006), provided in vivo evidence of VP55-medi-
ated polyadenylation (Figure 3E).
Determining the Interplay among miRNAs, RNAi, and
RNA Virus Infection
In an effort to characterize the biology of VSV-VP55 indepen-
dently of miRNA activity, we first compared multicycle growth
curves for VSV-VP55 and VSVctrl in cells lacking Dicer (Figures
4A and 4B). Administering the virus at a low moi of 0.01 for a
48 hr period resulted in no significant change in viral protein
levels (Figure 4A) or viral load, as both VSVctrl and VSV-VP55
replicated to comparable titers of 1 3 108 plaque-forming units
(pfu)/ml (Figure 4B). These data demonstrate that in the absence
of Dicer-generated small RNAs, VSV-VP55 and VSVctrl replicate
at comparable levels. As a result, we subsequently used these
two viruses to compare virus replication in Dicer-expressingCell Reports 8, 114–fibroblasts (Figures 4C and 4D). Surpris-
ingly, although previous studies have
implicated host miRNAs in the direct
silencing of VSV and RNAi activity in fibro-
blasts (Li et al., 2013; Otsuka et al., 2007),
we found that VSV-VP55 replication was
indistinguishable from VSVctrl replication,
again reaching approximately equal viral
protein levels (Figure 4C) and titers (Fig-
ure 4D). This was also true at earlier time
points postinfection (Figure S3). Taken
together, these results suggest that smallRNAs do not significantly impact the mammalian cellular
response to virus infection in vitro.
Next, we chose to study a homogeneous population of
physiologically relevant primary cells. As macrophages are an
important cell type for in vivo replication of VSV, we decided to
evaluate VSVctrl and VSV-VP55 in the context of a monocyte-
derived primary macrophage cell population (Junt et al.,
2007). Ex vivo infection of bone-marrow-derived macrophages
(BMMs) demonstrated comparable levels of infection as
measured by plaque assay (Figure 5A). Not surprisingly, small
RNA analysis of infected cohorts demonstrated a dramatic loss
of host miRNAs, including miR-142, miR-146, miR-155, and
miR-93, without impacting U6 RNA (Figure 5B). To ascertain
how loss of small RNAs in primary macrophages impacted the
cellular response to virus infection, we performed mRNA
sequencing (mRNA-seq) and compared the transcriptomes of
VSV infection in the presence and absence of small RNAs (Fig-
ure 5C; Table S2). In agreement with recent reports concerning
the indirect role of miRNAs in enhancing expression of host anti-
viral genes, we found the majority of transcripts that were
impacted the most by the expression of VP55 were canonical
ISGs (Seo et al., 2013). Interestingly, this virus-induced miRNA
‘‘targetome’’ included numerous guanylate-binding proteins
(Mx1, Mx2, Gbp5, Gbp7, and Gbp9), cytokines (TNFa, Cxcl10,
and Ccrl2), pyrogens (Il1b), and known components of the anti-
viral sensing and signaling machinery (Rsad2, Ifih1, Aim1,
Peli1, Csrnp1, Nlrc5, IRF1, Herc6, and Ddx60). Furthermore,
the differential host expression of these genes in the absence125, July 10, 2014 ª2014 The Authors 117
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Figure 3. Engineering VSV to Antagonize Small RNAs
(A) Schematic of VACV VP55 insertion into the VSV genome. Each independent transcript is shown as it would be generated. An, polyadenylated tail.
(B) Western blot analysis of VACV, VSVctrl, or VSV-VP55-infected BHK for VACV VP55, E3, and VSV G expression.
(C) Northern blot analysis of BHK coinfectedwith VSV expressingmiR-124 (VSV-124) and VACV, VSVctrl, or VSV-VP55 (moi of 1 for 12 hr) formiR-124, VSV-leader
RNA, and U6. Relative density depicts mature miR-124/U6.
(D) Analysis of murine fibroblasts transfected with control (scbl) or VSV-N-specific (VSV-N) siRNAs. At 6 hr posttransfection, cells were infected with VSVctrl or
VSV-VP55 for 10 hr (moi of 1). Western blot was probed for VSV proteins and actin.
(E) Schematic of pre-miR-146b-5p processing and the corresponding miRNA duplex (middle) and mature miRNAs (bottom). The mature miRNA sequence-
specific reads were determined by sequencing of the 20–25 nt fraction of VSV-VP55-infected cells. Adenosines (A) in black depict nontemplated bases and the
percent representation reflects the portion of the corresponding sequence in the total miRNA-specific tailed fraction.
See also Figure S2.of small RNAs could be independently corroborated by quantita-
tive PCR (qPCR; Figure 5D). Interestingly, this list includes tran-
scripts such as PTGS2, IRF1, Pim1, Nos2, Fndc3a, and Peli1,
which have already been independently implicated as miRNA
targets (Guo et al., 2012; Liu et al., 2013a, 2013b; Marquez
et al., 2010; Shan et al., 2009; Thomas et al., 2012). It is also note-
worthy that we identified only two genes that were expressed at
elevated levels in VSVctrl (Table S2), in agreement with the idea
that miRNAs are negative regulators of transcription (Bartel,
2004).
Defining the Contribution of Small RNAs In Vivo to the
Host Response to Virus Infection
Given the lack of an in vitro phenotype following disruption of
small RNA silencing (Figures 4 and 5), we next sought to deter-
mine whether RNAi contributes to the physiological response
to virus infection in vivo. To formally evaluate this possibility,
we first examined whether in vivo infection of VSV resulted in
the appearance of virus-specific small RNAs. To this end, we in-118 Cell Reports 8, 114–125, July 10, 2014 ª2014 The Authorsfected mice intranasally with VSVctrl or VSV-VP55 and deep
sequenced small RNAs between 18 and 25 nt. The resulting
data demonstrated the appearance of small RNAs comparable
to those observed in fibroblasts, albeit at vanishing rare levels
(Figure 6A; Table S3). Next, we investigated whether miRNA
tailing and degradation could be observed in vivo. For this pur-
pose, we chose to again ascertain the levels of miR-146. At
24 hr postinfection, total lung tissue from three independent an-
imals demonstrated a significant loss of miR-146, demonstrating
that, as previously reported (Backes et al., 2012), VP55 is suffi-
cient for targeting of small RNAs (Figure 6B).
In an effort to directly compare the contribution of small RNA
silencing to IFN signaling in the context of virus infection, we
generated a VSV strain to encode the NS1 protein of IAV, a
potent inhibitor of RIG-I and the subsequent induction of IFN
(Mibayashi et al., 2007; Pichlmair et al., 2006). VSV-NS1 and
VSV-VP55 were generated in an identical manner (Figure 3A).
In vitro infections of VSV-NS1 demonstrated that it produced
robust levels of NS1 and replicated to levels comparable to those
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Figure 4. Small RNAs Do Not Impact VSV
Replication
(A and B) Multicycle growth curve of VSVctrl and
VSV-VP55 (moi of 0.01) on dicer-deficient cells
(Dcr/).
(A) Cells were analyzed at the indicated time points
for expression of VSV proteins.
(B) Supernatants were analyzed at the indicated
time points by plaque assay.
(C and D) Multicycle growth curve of VSVctrl and
VSV-VP55 (moi of 0.01) on wild-type fibroblasts
(MEFs).
(C) Cells were analyzed at the indicated time points
for expression of VSV proteins.
(D) Supernatants were analyzed at the indicated
time points by plaque assay.
See also Figure S3.observed for VSVctrl and VSV-VP55 in immortalized fibroblasts
where IFN signaling was impaired (Figures S4A and S4B; Stojdl
et al., 2003). A similar phenotype was observed in dicer-deficient
cells (Dcr/) (Figure S4C). However, whereas infections of these
fibroblasts with either VSVctrl or VSV-VP55 resulted in robust in-
duction of IFNb, VSV-NS1 demonstrated a dramatic loss of cyto-
kine production, suggesting that NS1 was successfully targeting
RIG-I (Figure 6C).
The induction of IFNb in vitro also inversely correlated to virus
titers in both the lung and spleen (Figure 6D). That is, VSV-NS1, in
the absence of IFNb induction, replicated to levels greater than 1
log when compared with VSVctrl virus. Furthermore, VSV-VP55,
which demonstrated a modest increase in IFNb induction when
compared with VSVctrl, was reduced by a log in vivo (Figure 6D).
These results clearly illustrate the importance of IFN in the
mammalian response to virus.
In an effort to address whether redundancy in the antiviral
response systems failed to provide a fitness advantage to
VSV-VP55 in vivo, we next repeated our studies in mice lacking
both type I and III IFN systems (Figure 6E). To this end, we per-
formed intranasal infection of IFN-I and IFN-III receptor knockout
mice (Ifnar1//Il28r/) with VSVctrl, VSV-VP55, or VSV-NS1,
but found no significant differences in viral titers in the lung or
spleens of infected mice (Figure 6E). These data allow us to
conclude that the enhanced titers of VSV-NS1 in wild-type
mice was the result of muting the IFN response and, conversely,
that the attenuation of VSV-VP55 was a result of an enhanced
IFN response. Furthermore, the inability of VSV-VP55 to replicate
to titers exceeding those of VSVctrl, even in the absence of IFN-I
and IFN-III signaling, strongly suggests that a functional antiviral
RNAi system is not a physiological contributor to mammalian
antiviral defenses.Cell Reports 8, 114–DISCUSSION
The discovery that small RNAs have the
capacity to influence protein levels post-
transcriptionally ushered in a new era for
biology (Fire et al., 1998). Small RNA
silencing can be observed in diverse
biological processes, but predominantlyinvolves pathogen defense, achieving ‘‘transcriptional robust-
ness,’’ and maintaining distinct cellular lineages (Bartel and
Chen, 2004; Ebert and Sharp, 2012; Nayak et al., 2013).
The silencing potential of small RNAs is largely determined
by the extent of their target complementarity. Therefore,
genome-encoded miRNAs, which demonstrate only partial
complementarity to target genes, have significantly less capac-
ity to silence a transcript as compared with a vsiRNA, which
would be perfectly complementary (tenOever, 2013). For this
reason, the concept of miRNAs contributing to the antiviral de-
fenses of the cell is unlikely, because the modest repression
coupled with the average half-life of cellular proteins would
yield a limited overall impact during the context of acute virus
infection. This is not the case for viruses that can persist (Gott-
wein and Cullen, 2008). However, while miRNAs may not have
the capacity to directly silence a viral message, the cell’s ca-
pacity to process and utilize small RNAs has led to extensive
speculation as to whether mammals are capable of eliciting
an RNAi response. The idea of RNAi in mammals has been
further supported by reports that viral dsRNA-binding proteins
such as NS1, E3L, and VP35 can inhibit RNAi activity in both
plants and arthropods (Bucher et al., 2004; Chou et al., 2007;
Delgadillo et al., 2004; Li et al., 2004). Furthermore, with the
advent of deep sequencing, small RNA profiling has demon-
strated that many virus infections result in the accumulation
of genome-derived small RNAs, although in the case of
mammals, these RNAs were found to be independent of Dicer
(Parameswaran et al., 2010). It is also noteworthy that Drosha
has been reported to translocate from the nucleus to the cyto-
plasm in response to virus infection, but this activity did not
correlate with the appearance of virus-specific RNAs (Shapiro
et al., 2014).125, July 10, 2014 ª2014 The Authors 119
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Infection
(A–D) BMMs were infected with VSVctrl or VSV-VP55 (moi of 5).
(A) Viral replication was analyzed by plaque assay at the indicated time points.
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Relative density depicts miR-146/U6.
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protein-coding transcripts differentially regulated by VSV-VP55 infection are
shown.
(D) qRT-PCR depicting the levels of PTGS2, Ddx60, Rsad2, andMx1 induction
compared with endogenous tubulin levels in BMMs infected for 10 hr with
VSVctrl or VSV-VP55.
See also Table S2.
120 Cell Reports 8, 114–125, July 10, 2014 ª2014 The AuthorsMost recently, two reports demonstrated that RNase III gener-
ated vsiRNAs against EMCV and a mutant nodavirus (Li et al.,
2013; Maillard et al., 2013). Interestingly, one of these studies
suggested that RNAi was only a component of undifferentiated
stem cells and that this activity diminished as the cells became
responsive to IFN (Maillard et al., 2013). In contrast, the second
study found similar evidence for small RNA processing in termi-
nally differentiated hamster fibroblasts (Li et al., 2013). Together,
these studies put forth some provocative data hinting at the ex-
istence of an RNAi pathway in mammals, but neither study
demonstrated that the small RNAs detected mediated viral
cleavage in an antiviral fashion (Li et al., 2013). Furthermore,
both studies utilized multifunctional virus antagonists (B2 of
nodavirus and VP35 of Ebola), which have been shown to pro-
foundly impact the mammalian host response to virus indepen-
dently of small RNAs (Petrillo et al., 2013; Prins et al., 2010).
Given the importance of this question, we sought to formally
evaluate the mammalian response to virus to determine whether
RNAi is a physiological contributor to this process. To this end,
we generated two virus model systems using a vaccine strain
of VSV that is exquisitely sensitive to both IFN and RNAi (Mueller
et al., 2010; Vogel and Fertsch, 1987; Wilkins et al., 2005). For
this, we inserted the only known mammalian virus protein
capable of degrading small RNAs loaded into a RISC (VACV
VP55) or a RIG-I antagonist of IAV (IAV NS1). Insertion of VP55
or NS1 into VSV provided us with a unique tool to ascertain the
physiological role of small RNAs or IFN, respectively. Interest-
ingly, a VSV strain capable of eliminating host small RNAs was
found to replicate at a diminished capacity as compared with
control virus, in contrast to VSV-NS1, which replicated to levels
that exceeded 1 log over control. Although these results argue
against a role for RNAi in mammals, they are in agreement with
a recent publication concerning virus-induced polyribosylation
and shutdown of RISC, which also would argue against RNAi
functioning in mammals during times of stress (Leung et al.,
2011; Seo et al., 2013). Transcriptome profiling of VSV-VP55
and VSVctrl infections supports the idea that loss of RISC func-
tion results in a significant increase in a broad range of tran-
scripts, including a subset of ISGs. It should be noted that these
data do not suggest that loss of miRNAs leads to a specific up-
regulation in this class of genes, but rather that in the context of
infection, changes in ISG levels would be most prominent.
Lastly, to determine whether RNAi perhaps contributed a sec-
ondary response to IFN that would be masked in the context
of wild-type mice, we also tested our engineered viruses in
mice lacking both type I and III IFN systems. These results also
demonstrated that all viruses replicated to comparable levels,
suggesting that the small virus-derived RNAs that can be de-
tected in vivo are unlikely to contribute to the antiviral response
under physiological conditions.
Although it is difficult to prove the absence of a biological ac-
tivity, we believe our results put forth a strong argument against a
physiological RNAi antiviral response in mammals. In addition to
the results presented here, other studies have suggested a lack
of small RNA silencing in our antiviral defenses. Perhaps the
greatest support for this idea comes from the fact that viruses
can be targeted through the exploitation of host miRNAs (tenO-
ever, 2013). This technique, which has been employed by
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Figure 6. A Functional IFN Response Impacts VSV Replication
(A) RNA-seq reads (18–25 nt) obtained from the lungs of mice infected intranasally with VSVctrl or VSV-VP55 (1 3 107 pfu for 24 hr) aligned for their distribution
across the VSV-VP55 genome. GOI, gene of interest.
(B) Wild-typemice were infected intranasally with VSVctrl or VSV-VP55 (13 107 pfu; threemice per virus). At 24 hr postinfection, lungs were analyzed for miR-146
and U6 expression by northern blot. M1, mouse 1; M2, mouse 2; M3, mouse 3. Relative density depicts mature miR-146/U6.
(C) qRT-PCR depicting levels of IFN-b induction compared with endogenous tubulin levels in wild-type fibroblasts (MEFs) infected with VSVctrl, VSV-VP55, or
VSV-NS1 (moi of 1 for 16 hr).
(D) Wild-type mice were infected intranasally with VSVctrl, VSV-VP55, or VSV-NS1 (13 107 pfu). At 24 hr postinfection, the lungs and spleens were analyzed by
plaque assay. Statistical analysis was performed on indicated samples using a two-tailed, unpaired Student’s t test. Data are considered significant if the p value
is <0.05.
(E) INF-I and INF-III receptor knockout mice (Ifnar1//Il28r/) were infected intranasally with VSVctrl, VSV-VP55, or VSV-NS1 (1 3 104 pfu). At 48 hr post-
infection, the lungs and spleens were analyzed by plaque assay. Statistical analysis was performed on indicated samples using a two-tailed, unpaired Student’s t
test. Data are considered significant if the p value is <0.05.
See also Figure S4 and Table S3.countless groups and in a wide range of viruses, requires RISC
function to be intact during infection, at least for the initial hours
preceding viral transcription. If RNAi in mammals is detrimental
to virus infection, one would postulate that this aspect of RISC
function would be antagonized by viruses as is the case for
IFN. In addition to this anecdotal support, other aspects of
mammalian biology suggest that RNAi is unlikely to contribute
to the antiviral response. First, it has been demonstrated that
expression of an RdRp in mammalian cells is sufficient to induce
IFN-I in the absence of infection (Yu et al., 2012). RdRp function
in plants and worms is used to generate and amplify vsiRNAs
(Carthew and Sontheimer, 2009; Schwach et al., 2005). Although
flies maintain an RNAi response in the absence of vsiRNA ampli-fication or an RdRp, they compensate for this by modifying their
small RNAs via 20-O-methylation to extend the half-life of the
small RNAs and use them in a systemic manner (Ameres et al.,
2010; Saleh et al., 2009). However, in contrast to flies and plants,
mammals only utilize this chemistry on Piwi-interacting RNAs in
stem and germ cells (Aravin and Hannon, 2008). Taken together,
these studies suggest that the evolution of chordates involved
a dramatic modification of how our cells respond to virus
infection.
It is noteworthy, however, that while RNAi does not perform a
physiological role in the antiviral response, this lack of interplay
provides us with some valuable resources. One example of
such a resource is the VSV-VP55 virus used in these studies.Cell Reports 8, 114–125, July 10, 2014 ª2014 The Authors 121
Transcriptome profiling of infected cells allowed us to accurately
map the miRNA targetome in infected cells from an in vivo infec-
tion. The addition of VP55 to more inert vectors, such as a lenti-
virus or adenovirus, may also be useful for similar studies.
Furthermore, the lack of interplay between small RNAs and
mammalian viruses allows one to exploit the small RNA pathway
to control tropism, produce vaccines, or create layers of biocon-
tainment (Lauring et al., 2010; tenOever, 2013). In addition, the
lack of interplay between mammalian viruses and the small
RNA machinery also makes these vectors ideal for the delivery
of small RNAs (Schmid et al., 2014). The ability to deliver
siRNAs is a critical need in the medical field, and the recent dis-
covery that RNA viruses can also be engineered to encode
siRNAs and utilize the small RNA host machinery makes this a
provocative option for future therapeutics.
EXPERIMENTAL PROCEDURES
Cells, Viruses, and Infections
Vero, baby hamster kidney (BHK), RAW, murine wild-type fibroblast (MEF),
and murine dicer-deficient (DCR/) cells were grown at 37C in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin. The dicer-deficient cells were a kind gift
from Dr. P. Sharp (Massachusetts Institute of Technology) (Calabrese et al.,
2007). For the generation of BMMs, femurs were removed from naive mice
and BM cells were cultured for a minimum of 10 days in RPMI containing
20% (vol/vol) FBS, L-glutamine, and 30% (vol/vol) conditioned media from
L929 cells. VSV142T and VSVscbl were generated as previously described
(Kelly et al., 2008). VSV expressing VACV VP55 (VSV-VP55), IAV NS1 (VSV-
NS1), and a same-size RNA insert not encoding for an open reading frame
(VSVctrl) were generated and rescued as previously described (Stojdl et al.,
2003). Generation of VSV expressing miR-124 has been described elsewhere
(Langlois et al., 2012a). Infections with VSV (strain Indiana), VACV (strainWest-
ern Reserve), SV, and IAV (A/PR/8/34) were performed at the indicated moi
at 37C.
In Vivo Infections
C57BL/6 mice were purchased from Taconic. Ifnar1//Il28r/ mice
have been described elsewhere (Mordstein et al., 2010). Mice were anesthe-
tized with isoflurane and infected intranasally with 1 3 104 (Ifnar1//Il28r/)
or 13 107 (C57BL/6) pfu of VSV. Lungs and spleens were removed on the indi-
cated days postinfection and homogenized in 500 ml PBS for analysis by pla-
que assay or in 1 ml Trizol for analysis by northern blot and small RNA deep
sequencing. All experiments involving animals were done in accordance
with the guidelines of the Mount Sinai School of Medicine Institutional Animal
Care and Use Committee.
Western Blot and Small RNA Northern Blot
Western blots were generated from total protein separated on a 12% SDS-
PAGE gel. Resolved protein was transferred to nitrocellulose (Bio-Rad),
blocked for 1 hr with 5% skim milk at 25C, and then incubated with the indi-
cated antibody overnight at 4C. The polyclonal VSV antibody (a kind gift from
Dr. J. Bell, University of Ottawa, Ottawa, Canada) and VACV VP55 antibody (a
kind gift fromDr. R. Condit, University of Florida, Gainesville, FL) were used at a
1:5,000 dilution. The VACV E3L antibody (NR-4547; BEI Resources), IAV NS1
antibody (1A7; MSSM Hybridoma Center), and anti-pan-actin antibody
(Neomarkers) were used at a 1:2,000 dilution. Secondary mouse and rabbit
antibodies (GE Healthcare) were used at a 1:5,000 dilution for 1 hr at 25C.
All antibodies were diluted in 5% skim milk. Immobilon Western Chemolumi-
nescent HRP substrate (Millipore) was used as directed.
Small RNA northern blots and probe labeling were performed as described
previously (Pall and Hamilton, 2008). The probes used included anti-miR-124:
50-TGGCATTCACCGCGTGCCTT AA-30; anti-U6: 50-GCCATGCTAATCTTC
TCTGTATC-30; anti-miR-146: 50-AACCCATGGAATTCAGTTCTCA-30; anti-122 Cell Reports 8, 114–125, July 10, 2014 ª2014 The AuthorsmiR-155: 50-ACCCCTATCACAATTAGCATTAA-30; anti-miR-142: 50-TCCAT
AAAGTAGGAAACACTACA-30; anti-miR-93: 50-CTACCTGCACGAACAGCA
CTT TG-30; anti-miR-21: 50-TCAACATCAGTCTGATAAGCTA-30; anti-miR-24:
50-CTGTTCCTGCTGAACTGAGCCA-30; anti-VSV leader RNA: 50-GTTTCTCC
TGAGCCTTTTAATGATAATAATGGTTTGTTTGTCTTCGT-30; anti-VSV318: 50-TC
CGAAACTTGACCAATCTTTA-30; and anti-VSV11161: 50-TATCTGGTTTTGTGG
TCTTCGT-30.
VSV Plaque Assay
VSV was inoculated into the indicated cell lines containing serum-free DMEM
for 1 hr. The inoculum was then aspirated off and replaced with complete
medium for the indicated times. Briefly, cells were infected with VSV (moi
as indicated) and 0.25 ml of supernatant was removed at the indicated times.
Supernatant was plaqued in Vero cells in serial dilutions in triplicate in 1%
methylcellulose. Plaques were counted at 3 days postinfection. Error bars
represent the SD (n = 3) and p values were calculated based on a two-tailed
t test.
qRT-PCR
qRT-PCR for VSV M (primers 50-GCGGTATTGGCAGATCAAGGT-30 and 50-
CCCCATCCTATGTGGCAAAT-30), IFN-b (primers 50- AGATGTCCTCAACT
GCTCTC-30 and 50- AGATTCACTACCAGTCCCAG-30 ), PTGS2 (primers 50-
GTCAGGACTCTGCTCACGAA-30 and 50-AGGATTTGCTGCCTGGCTGA-30,
Ddx60 (primers 50- GTCTCCTGTGGTCGACTGTG-30 and 50- AATGTCGT
ATCGGGAAGCCC-30 ), Rsad2 (primers 50-TGGCCGTGGTCAAGGAAAAA-30
and 50- GGAAAACCTTCCAGCGCAC-30), and MX1 (primers 50-ACCTCCCA
CATCTGTAAATCACT-30 and 50- GTATGTCTGCACCGTACTTCTG-30) of com-
plementary DNA samples was performed using KAPA SYBR FAST qPRC
Master Mix (KAPA Biosystems). PCRs were performed on a Mastercycler ep
realplex (Eppendorf). Murine tubulin (primers 50-TGCCTTTGTGCACTGG
TATG-3 and 50-CTGGAGCAGTTTGACGACAC-30) was used as the endoge-
nous housekeeping gene, and Delta Delta cycle threshold (DDCT) values
were calculated with replicates over tubulin. Values represent the fold change
over mock-infected samples.
RNAi and Transfections
Chemically unmodified anti VSV-NP siRNA (IDT; 50-TTTCCCGATGTTTATT
CC-30) was transfected into BHK cells in suspension using RNAiMAX
(Invitrogen).Cellswere infectedwithVSVat 6hr posttransfection and harvested
at 10 hr postinfection. Plasmids were transfected into cells in suspension using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Small RNA Deep Sequencing and mRNA-Seq Analysis
Deep sequencing was performed on wild-type murine fibroblasts (18–25 nt
fraction) infected with VSV, SV, or IAV at an moi of 1 for 12 hr on C6 glial cells
persistently infected with BDV (He/80) (18–25 nt fraction) or onmouse lungs in-
fected with VSVctrl or VSV-VP55 (18–25 nt fraction). Isolation, purification, and
amplification of small RNA species were performed as previously described
(Langlois et al., 2012b). Small RNA libraries were generated as previously
described (Pfeffer et al., 2004). Briefly, total RNA from indicated samples
was isolated using TRIzol (Invitrogen) and spiked with radiolabeled size
markers prior to size fractionation on a 12% denaturing Tris-urea gel (Sequa-
Gel; National Diagnostics). RNA was separated by electrophoresis on a 15%
TBE-urea gel, and RNA molecules 17–26 nt were excised and eluted from
the gel fragments. Following ethanol precipitation, small RNA-seq libraries
were produced using the Small RNA Sample Prep v1.5 kit (Illumina) according
to the manufacturer’s instructions. RNA-seq was performed on BMMs in-
fected with VSV at an moi of 5 for 10 hr. RNA extracts were prepared using
standard mRNA-seq protocols (Cat. No. 1502062; Illumina). Briefly, mRNA
was isolated from 1 mm of RNA using sera oligo-dT beads. This was then
used for cDNA synthesis with SuperScript II reverse transcriptase (Life Tech-
nologies). This was followed by second-strand synthesis, end repair, A-tailing,
ligation, and PCR using the Illumina Truseq kit. Amplification of the cDNA
library was checked using the Bioanalyzer DNA 1000 Assay. mRNA-seq li-
braries were clustered with cBOT (Illumina) and then run on HiSeq (Illumina)
for 100-base single-read sequencing.
Statistical Analysis
Statistical analysis was performed on the indicated samples using a two-
tailed, unpaired Student’s t test. Data are considered significant if the p value
is < 0.05.
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